A Study With CIT-013 in RA Patients

This study tests an investigational drug called CIT-013 in people with rheumatoid arthritis (RA), a condition where the immune system attacks the joints, causing pain and swelling. The study wants to find out if CIT-013 can reduce joint inflammation in people who are already taking standard RA medications. **You may be eligible if:** - You are between 18 and 85 years old - You have been diagnosed with rheumatoid arthritis for at least 3 months - You have active disease with swollen and tender joints and elevated inflammation markers (CRP) - You have been on a stable dose of a conventional RA medication for at least 3 months **You may NOT be eligible if:** - Your RA is so severe that you need to start a biological drug (like a TNF inhibitor) right away - You have another active inflammatory joint disease (other than RA) - You have recently used a biological or targeted RA drug without an adequate washout period - There is a contraindication to CIT-013 for you specifically Talk to your doctor to see if this trial is right for you.